Virtual Library

Start Your Search

Y. Matsui



Author of

  • +

    P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P1.04-015 - Pleomorphic Carcinoma of the Lung: A Clinicopathologic Study of 23 Resected Cases (ID 2103)

      09:30 - 17:00  |  Author(s): Y. Matsui

      • Abstract
      • Slides

      Background:
      Pleomorphic carcinoma (PC) of the lung is rare, and it is classified as a subtype of sarcomatoid carcinoma of the lung in the WHO histologic classification of lung tumors. We here demonstrated the clinicopathologic characteristics of PC surgically resected in our hospital.

      Methods:
      In this study, 23cases (2.3%) of PC among 968 of non-small cell lung cancer surgically resected at the Kitasato University Hospital between January 2004 and January 2015 were reviewed. The registry data of the patients with PC were analyzed, and the clinicopathologic profiles and surgical outcomes of the patients were evaluated.

      Results:
      There were 19 men and 4 women, and their mean age was 64 years (range: 39 to 81 y). All but two patients were smoker, and their mean smoking index was 41 pack year. In this study, the mean diameter of the tumor was 48.8 mm; tumors over 50 mm in diameter comprised 45% of all cases. The TNM pathological stages of PC were classified as: 2 (9%) cases with stage IA, 5 (22%) with stage IB, 2 (9%) with stage IIA, 8 (35%) with stage IIB, 5 (22%) with stage IIIA, and 1 (4%) with stage IIIB carcinoma. Ten tumors contained identifiable epithelial components, and the other 12 consisted of spindle cells and giant cells alone: an adenocarcinoma component was found in 11 cases, and 4 of the 11 cases had a coexisting squamous cell carcinoma component. In all the 23 patients, lymphatic infiltration and/or venous infiltration were evident. Overall follow-up ranged from 60 to 2605 days, with a median (for patients still alive) of 896 days. The overall survival rate and disease-free survival rate were 65% and 57%, respectively. Furthermore, 58% of the clinical stage I patients with PC demonstrated advance in the pathological stage. Cancer recurrence was identified in 6 patients; local or local with distant recurrence in one each and distant in 4.

      Conclusion:
      We concluded that PC should be considered as an aggressive disease and vascular infiltration should be usually reported and used as a factor in clinical assessments.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.